Vontobel Holding
VRTX icon

Vontobel Holding’s Vertex Pharmaceuticals VRTX Stock Holding History

Vontobel Holding’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44.5M Buy
85,083
+3,558
+4% +$1.82M 0.16% 134
2026
Q2 		$40.5M Sell
81,525
-1,855
-2% -$822K 0.13% 157
2026
Q1 		$37.2M Sell
83,380
-21,907
-21% -$10.2M 0.13% 150
2025
Q4 		$47.7M Sell
105,287
-5,355
-5% -$2.31M 0.15% 119
2025
Q3 		$43.3M Buy
110,642
+38,844
+54% +$16.2M 0.13% 117
2025
Q2 		$32M Sell
71,798
-3,008
-4% -$1.39M 0.1% 150
2025
Q1 		$36.3M Sell
74,806
-114,143
-60% -$53.2M 0.13% 119
2024
Q4 		$76.1M Buy
188,949
+75,653
+67% +$35.1M 0.26% 64
2024
Q3 		$52.7M Sell
113,296
-45,534
-29% -$21.9M 0.17% 102
2024
Q2 		$74.4M Buy
158,830
+50,450
+47% +$21.9M 0.24% 65
2024
Q1 		$45.3M Buy
108,380
+46,946
+76% +$19.8M 0.36% 72
2023
Q4 		$25M Sell
61,434
-6,200
-9% -$2.29M 0.21% 121
2023
Q3 		$23.5M Sell
67,634
-363
-0.5% -$127K 0.22% 119
2023
Q2 		$23.9M Buy
67,997
+10,387
+18% +$3.5M 0.21% 122
2023
Q1 		$18.2M Sell
57,610
-5,089
-8% -$1.53M 0.17% 142
2022
Q4 		$17.9M Buy
62,699
+3,573
+6% +$1.09M 0.18% 137
2022
Q3 		$17.3M Sell
59,126
-13,662
-19% -$3.93M 0.2% 118
2022
Q2 		$20.4M Sell
72,788
-17,903
-20% -$4.79M 0.22% 112
2022
Q1 		$23.3M Sell
90,691
-26,006
-22% -$6.17M 0.2% 111
2021
Q4 		$26M Buy
116,697
+18,953
+19% +$3.69M 0.22% 106
2021
Q3 		$17.7M Buy
97,744
+19,318
+25% +$3.77M 0.16% 129
2021
Q2 		$15.4M Buy
78,426
+11,786
+18% +$2.47M 0.13% 137
2021
Q1 		$14.3M Buy
66,640
+8,572
+15% +$1.88M 0.11% 131
2020
Q4 		$12.4M Buy
+58,068
New +$13.3M 0.08% 155

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Vontobel Holding's VRTX Position: Q3 2026 in Review

Vontobel Holding increased its Vertex Pharmaceuticals (VRTX) stake by 4.4% in Q3 2026, buying an estimated $1.82M and bringing the position to 85,083 shares worth $44.5M. The position accounts for 0.16% of the portfolio, ranked #134.

Vontobel Holding first reported a position in VRTX in Q4 2020 and has held it in 24 quarters since. The position peaked at $76.1M in Q4 2024. 1,127 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Vontobel Holding held 85,083 shares of Vertex Pharmaceuticals worth $44.5M as of Q3 2026.
  • Vontobel Holding bought 3,558 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.82M.
  • Vertex Pharmaceuticals made up 0.16% of Vontobel Holding's portfolio in Q3 2026, its #134 holding.
  • Vontobel Holding first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 24 quarters since.
  • Vontobel Holding's Vertex Pharmaceuticals position peaked at $76.1M in Q4 2024.
  • 1,127 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Vontobel Holding's 13F filing for Q3 2026, filed 16 Oct 2026.